Tamara Raińska-Giezek, Karolina Kłoda, Paweł Kawalec, Andrzej Kusak, Andrzej Pawlik
Pochodne tiazolidynodionów w leczeniu cukrzycy typu 2
Thiazolidinedione derivatives in the treatment of type 2 diabetes. Thiazolidinedione derivatives (TZDs) pioglitazone and roziglitazone have been approved for the treatment of type 2 diabetes mellitus either as monotherapy for patients with intolerance or contraindications to metformin or in combination therapy. There are especially suitable for obese patients but this implies that TZDs are not first-choice monotherapy. Their efficacy with respect to blood glucose lowering is comparable with sulphynylurea derivatives and with metformin. There is still not enough data with respect to efficacy and side effects of this class of drugs.